Ken Griffin Dyne Therapeutics, Inc. Transaction History

Citadel Advisors LLC

$618 Billion
Q3 2025

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Dyne Therapeutics, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 3,413,435 shares of DYN stock, worth $64.3 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

3,413,435

Previous 943,874 261.64%

Holding current value

$64.3 Million

Previous $8.99 Million 380.57%

% of portfolio

0.01%

Previous 0.0%

21 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 14, 2025	BUY	$8.18 - $14.22 $20.2 Million - $35.1 Million	2,469,561 Added 261.64%	3,413,435 $43.2 Million
Q2 2025 Aug 14, 2025	SELL	$6.81 - $14.78 $14.1 Million - $30.5 Million	-2,065,515 Reduced 68.64%	943,874 $8.99 Million
Q1 2025 May 15, 2025	BUY	$10.46 - $25.46 $1.55 Million - $3.76 Million	147,808 Added 5.17%	3,009,389 $31.5 Million
Q4 2024 Feb 14, 2025	SELL	$23.56 - $35.55 $1.83 Million - $2.76 Million	-77,759 Reduced 2.65%	2,861,581 $67.4 Million
Q3 2024 Nov 14, 2024	SELL	$31.94 - $47.04 $44 Million - $64.8 Million	-1,376,666 Reduced 31.9%	2,939,340 $106 Million

Q2 2024 Aug 14, 2024	BUY	$23.65 - $35.63 $1.46 Million - $2.2 Million	61,730 Added 1.45%	4,316,006 $152 Million
Q1 2024 May 15, 2024	BUY	$13.06 - $29.18 $15.7 Million - $35 Million	1,200,836 Added 39.33%	4,254,276 $121 Million
Q4 2023 Feb 14, 2024	BUY	$6.62 - $13.64 $78,341 - $161,415	11,834 Added 0.39%	3,053,440 $40.6 Million
Q3 2023 Nov 14, 2023	BUY	$8.6 - $12.18 $2.89 Million - $4.09 Million	335,603 Added 12.4%	3,041,606 $27.3 Million
Q2 2023 Aug 14, 2023	SELL	$8.53 - $14.28 $2.75 Million - $4.61 Million	-322,797 Reduced 10.66%	2,706,003 $30.4 Million
Q1 2023 May 15, 2023	BUY	$10.88 - $15.0 $1.29 Million - $1.78 Million	118,721 Added 4.08%	3,028,800 $34.9 Million
Q4 2022 Feb 14, 2023	SELL	$9.37 - $13.8 $115,185 - $169,643	-12,293 Reduced 0.42%	2,910,079 $33.7 Million
Q3 2022 Nov 14, 2022	SELL	$7.2 - $15.17 $24,062 - $50,698	-3,342 Reduced 0.11%	2,922,372 $37.1 Million
Q2 2022 Aug 15, 2022	SELL	$4.36 - $10.5 $159,658 - $384,499	-36,619 Reduced 1.24%	2,925,714 $20.1 Million
Q1 2022 May 16, 2022	BUY	$6.52 - $12.27 $639,827 - $1.2 Million	98,133 Added 3.43%	2,962,333 $28.6 Million
Q4 2021 Feb 14, 2022	SELL	$11.89 - $16.07 $112,681 - $152,295	-9,477 Reduced 0.33%	2,864,200 $34.1 Million
Q3 2021 Nov 15, 2021	SELL	$15.6 - $21.46 $668,257 - $919,282	-42,837 Reduced 1.47%	2,873,677 $46.7 Million
Q2 2021 Aug 16, 2021	SELL	$15.94 - $22.33 $2.85 Million - $4 Million	-179,066 Reduced 5.78%	2,916,514 $61.4 Million
Q1 2021 May 17, 2021	SELL	$14.0 - $29.3 $962,360 - $2.01 Million	-68,740 Reduced 2.17%	3,095,580 $48.1 Million
Q4 2020 Feb 16, 2021	BUY	$16.81 - $23.94 $3.29 Million - $4.69 Million	195,927 Added 6.6%	3,164,320 $66.5 Million
Q3 2020 Nov 16, 2020	BUY	$20.0 - $23.9 $59.4 Million - $70.9 Million	2,968,393 New	2,968,393 $59.9 Million

Others Institutions Holding DYN

# of Institutions

227

Shares Held

148M

Call Options Held

184K

Put Options Held

243K

View Full List

About Dyne Therapeutics, Inc.

Ticker DYN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 51,765,400
Market Cap $975M
Description
Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and...

More about DYN

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account